Stuart Sprague, DO
Nephrology · Evanston, ILNPI 1114947124
Payments from drug & device makers
Across 540 payments — averaging $1123.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$148K
- Amgen$98K
- AstraZeneca$65K
- OPKO Pharmaceuticals, LLC$64K
- Takeda Pharmaceuticals U.S.A., Inc.$61K
- Bayer$49K
- plus $123K from 27 others
Across 1 payment — averaging $38,848 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ardelyx, Inc.$39K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 63 | $147,762 |
| Amgen(2 entities) | 101 | $97,962 |
| AstraZeneca(2 entities) | 53 | $65,170 |
| OPKO Pharmaceuticals, LLC | 38 | $63,729 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $60,778 |
| Bayer | 47 | $48,786 |
| Fresenius USA Marketing, Inc. | 34 | $26,574 |
| Kyowa Kirin, Inc. | 29 | $20,188 |
| Beigene USA, Inc. | 7 | $17,525 |
| Aurinia Pharma U.S., Inc. | 10 | $14,799 |
| Novartis | 8 | $10,269 |
| Biogen | 1 | $9,186 |
| Shire North American Group Inc | 9 | $7,666 |
| Ultragenyx Pharmaceutical Inc. | 7 | $4,643 |
| Beone Medicines USA, Inc. | 1 | $4,250 |
| Ascendis Pharma Endocrinology Inc | 4 | $3,641 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 1 | $1,400 |
| Travere Therapeutics, Inc. | 28 | $789 |
| GSK | 5 | $304 |
| Mallinckrodt Hospital Products Inc. | 6 | $229 |
| Calliditas Therapeutics US Inc. | 9 | $185 |
| Akebia Therapeutics Inc | 3 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $170 |
| Novo Nordisk | 2 | $141 |
| ANI Pharmaceuticals, Inc. | 5 | $124 |
| Vifor Pharma, Inc. | 4 | $123 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Alvogen Inc | 1 | $24 |
| Recor Medical Inc | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$606,715 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Evanston
- Myles WolfChicago$22.4M
- Suneel UdaniHinsdale$6.8M
- Paul CrawfordEvergreen Park$3.1M
- Beatrice ConcepcionChicago$2.6M
- April KennedyChicago$1.8M
- Khaleel SayeedChicago$1.7M
- Woojin James ChonHines$1.1M
- Mohammed AhmedBolingbrook$1.1M
- Tamara IsakovaChicago$763K
- William WhittierChicago$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.